Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
SVRA
Savara
$3.53
Login to display Savara (SVRA) recommendation from the last 90 days from financial news and social media. Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Chart
$3.42 (+3.22%)
$2.27 (+55.51%)
$3.22 (+9.63%)
$3.66 (-3.55%)
SVRA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
SVRA overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SVRA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SVRA Street view is unimpressive but have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displaySVRA Earnings
The TTM reflects 12-month period, providing review of SVRA financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is SVRA current stock price?
What are SVRA stock strengths?
What risks are associated with SVRA stock?
When is SVRA next earnings report?
What is SVRA market cap and volume?
What is SVRA's current Stock IQ?
Should I buy SVRA stock right now?
Is SVRA a Strong Buy right now?
What does a 'Strong Buy' rating mean for SVRA?
What does a 'Strong Sell' rating mean for SVRA?
What factors influence SVRA's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
SVRA
Savara
Current Price
$3.53
Stock Insights
Strengths
Earnings are forecast to grow
Upgraded on attractively valued
Login to view Savara (SVRA) recommendation from the last 90 days from financial news and social media.
Chart
$3.42 (+3.22%)
$2.27 (+55.51%)
$3.22 (+9.63%)
$3.66 (-3.55%)
SVRA Analysts Opinion
SVRA Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
SVRA Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SVRA Street view is unimpressive but have positive views on the near-term outlook
SVRA has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Price under $5
Average key support and resistance price levels.
Login to displaySVRA Earnings
The TTM data reflects the most recent 12-month period, providing overview of SVRA financial performance.
SVRA Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
SVRA Latest Analysis
Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025. – The Beneficial Clinical Effects of Molgramostim Were Similar in Patients with aPAP Regardless of Disease Severity Defined by DLco% –– Changes in DLco% the Primary Endpoint in IMPALA-2 Were Significantly Correlated with Changes in Measures of Quality of Life
Mon Sep 29, 2025
Deadline Approaching: Savara Inc. (SVRA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith. Law Offices of Howard G. Smith reminds investors of the upcoming November 7 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Savara Inc. (Savara or the Company) (NASDAQ: ) securities between March 7 2024 and May 23 2025 inclusive (the Class Period).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN SAVARA INC. (SVRA) CONTACT THE LAW OFF
Tue Sep 16, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
SVRA Stock trends
SVRA Stock performance
SVRA Stock analysis
SVRA investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings